foxo4-dri senolytic peptide human trial 2024

foxo4-dri senolytic peptide human trial 2024 Buy 10mg | Third-Party Tested The disordered p53 transactivation domain

Name: foxo4-dri senolytic peptide human trial 2024 Buy 10mg | Third-Party Tested The disordered p53 transactivation domain
Brand: ldesquadrias.com.br
SKU: 27261777984
Price: 20.84 USD
Availability: InStock
Rating: 4.804600000000001 (8 reviews)

The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4 DRI Nature Communications FOXO4 DRI 10mg vial Description RCpeptides FOXO4 peptide targets myofibroblast ameliorates bleomycininduced pulmonary fibrosis in mice through ECMreceptor interaction pathway Han 2022 Journal of Cellular and Molecular Medicine Wiley Online Library FOXO4 DRI alleviates age related testosterone secretion insufficiency by targeting senescent Leydig cells in aged mice Aging FOXO4 DRI induces keloid senescent fibroblast apoptosis by promoting nuclear exclusion of upregulated p53 serine 15 phosphorylation Communications Biology FOXO4 DRI: Human Trial Status, Cancer Research & Senolytic Data

SKU: 27261777984 · From ldesquadrias.com.br

4.8

USD20.84 USD44.84

Pay in 4 interest-free payments of $5.21 Learn more

Shipping Estimate
USA

USA

CAN

Ships within 48 hours · Estimated delivery Aug 14 - Aug 19

Description

We found that the annual publication trend in China closely mirrored the global trend, with China consistently leading in publication volume each year